CareDx Inc (CDNA)vsWaters Corporation (WAT)
CDNA
CareDx Inc
$63.68
+3.76%
HEALTHCARE · Cap: $3.17B
WAT
Waters Corporation
$433.54
+0.75%
HEALTHCARE · Cap: $41.62B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 914% more annual revenue ($4.64B vs $458.09M). CDNA leads profitability with a 24.2% profit margin vs 3.6%. CDNA trades at a lower P/E of 26.1x. CDNA earns a higher WallStSmart Score of 53/100 (C-).
CDNA
Buy53
out of 100
Grade: C-
WAT
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.0%
Fair Value
$61.69
Current Price
$63.68
$1.99 discount
Margin of Safety
-45.9%
Fair Value
$225.66
Current Price
$433.54
$207.88 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 52.2% year-over-year
Conservative balance sheet, low leverage
Keeps 24 of every $100 in revenue as profit
Revenue surging 113.4% year-over-year
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Moderate valuation
0.0% earnings growth
Operating margin of 0.2%
ROE of -2.6% — below average capital efficiency
Expensive relative to growth rate
ROE of 1.1% — below average capital efficiency
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.2% and operating margin at 0.2%. Revenue growth of 52.2% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 113.4% demonstrates continued momentum.
Bear Case : CDNA
The primary concerns for CDNA are P/E Ratio, EPS Growth, Operating Margin.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Profit Margin. A P/E of 107.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
CDNA profiles as a growth stock while WAT is a hypergrowth play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.43 — expect wider price swings.
WAT is growing revenue faster at 113.4% — sustainability is the question.
WAT generates stronger free cash flow (153M), providing more financial flexibility.
Bottom Line
CDNA scores higher overall (53/100 vs 45/100), backed by strong 24.2% margins and 52.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?